Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Enzon Pharmaceuticals ( (ENZN) ) has issued an update.
On September 30, 2025, Enzon Pharmaceuticals, Inc. announced the Fifth Amendment to its Section 382 Rights Agreement, originally established on August 14, 2020, with Continental Stock Transfer & Trust Company as the rights agent. This amendment extends the Final Expiration Date of the rights from September 30, 2025, to December 31, 2025. The amendment reflects the company’s management belief that this extension is in the best interests of the company and its stockholders.
More about Enzon Pharmaceuticals
Average Trading Volume: 38,271
Technical Sentiment Signal: Sell
Current Market Cap: $5.93M
See more insights into ENZN stock on TipRanks’ Stock Analysis page.